Medical device firm Optovue has introduced new optical coherence tomography angiography (OCTA) technology, AngioAnalytics.

Available on the the AngioVue imaging system, the new OCTA technology allows clinicians to quantify the density of blood flow in the retina, the light-sensitive portion of the eye.

This will help clinicians to manage diseases, which cause progressive blindness such as diabetic retinopathy or acute macular degeneration.

Optovue founder and CEO Jay Wei said: "The availability of our breakthrough AngioAnalytics technology raises the standard of care available to patients while improving practice workflow and diagnostic confidence.

"With the addition of AngioAnalytics to the AngioVue system, clinicians now have objective data regarding the areas encompassed by flow and non-flow regions, as well as a visual map of the blood flow in the retina."

OCTA technology deploys light rays to form detailed three-dimensional images of the retina, allowing physicians to quickly visualize the anatomic structures and abnormalities present.

The AngioVue system captures a single image within three seconds, which complements the current angiography imaging standard, fluorescein angiography (FA).

According to the company, the AngioVue system was installed and incorporated into daily clinical use at around 500 sites across the US.